With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalyst Pharmaceuticals and its potential blockbuster Firdapse for $4.1 billion. More: Angelini finds Catalyst for its US growth ambitions with .1B buyout Source: fierce
read more
Partnership builds on existing collaboration and adds two new UCB‑nominated projects More: UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies Source: News
read more
Nihr‑funded phase 2 study to assess progesterone delivery using Callavid device More: Calla Lily Clinical Care begins dosing in trial of intravaginal platform for threatened miscarriage Source: News
read moreAfter a surprise rejection in January, the FDA has agreed to reconsider a T-cell therapy based on the same single-arm trial that the agency had previously found problematic. The case could reignite investors’ hope of a potential reversal for uniQure’s
read moreThe FDA has hit Alnylam with an untitled letter over the consumer website for Amvuttra, accusing the biotech of presenting open-label data that create a misleading impression of the drug’s effects. More: Alnylam rebuked by FDA over efficacy claims on
read moreInsulet has always been a strong leader in the medtech industry when it comes to its marketing game—and the diabetes device maker isn’t looking to rest on its laurels. More: Insulet CEO details ‘Scrubs’ device promotion win as it boosts
read more© 1994 - 2026 B.M. Pharmaceuticals